{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'Table of Contents', 'TABLE OF CONTENTS', '7', 'ABBREVIATIONS', '10', '1', 'TRIAL SUMMARY', '12', '2', 'TRIAL DESIGN', '20', '2.1', 'Trial Design', '20', '2.2', 'Trial Scheme', '21', '2.3', 'Schedule of Trial Activities', '22', '3', 'OBJECTIVES(S), HYPOTHESIS(ES), AND ENPOINT(S)', '26', '3.1', 'Primary Objective, Hypothesis, and Enppoint', '26', '3.2', 'Secondary Objective(s), Hypothesis(es), and Endpoint(s)', '26', '3.3', 'Exploratory Objective', '27', '4', 'BACKGROUND AND RATIONALE', '28', '4.1', 'Colorectal Cancer Incidence', '28', '4.2', 'Treatment Options for Colorectal Cancer', '28', '4.2.1', 'Fluoropyrimidine plus Oxaliplatin Regimes in Metastatic Colorectal Cancer', '28', '4.2.2 Further Treatment Options for Metastatic Colorectal Cancer', '29', '4.3', 'Rationale', '29', '4.3.1', 'Rationale for FOLFOX or FOLFOXIRI as post-resection/ablation therapy', '29', '4.3.2', 'Rationale for Study Design and Endpoints', '30', '4.4', 'Ethical Considerations and Benefit-Risk Assessment', '31', '5', 'METHODOLOGY', '32', '5.1', 'Trial Population', '32', '5.1.1', 'Inclusion Criteria', '32', '5.1.2', 'Exclusion Criteria', '33', '5.1.3', 'Lifestyle Considerations', '35', '5.1.4', 'Pregnancy', '35', '5.2', 'Trial Intervention(s)', '35', '5.2.1', 'Timing of Dose Administration', '36', '5.2.2', 'Prerequisites for Application of Trial Intervention', '36', '5.2.3', 'Treatment Modification and Toxicity Management of FOLFOX/FOLFOXIRI', 'Chemotherapy', '37', '5.3', 'Methods against Bias', '38', '5.3.1 Minimizing Selection Bias', '38', '5.3.2', 'Minimizing measurement bias', '39', '5.4', 'Concomitant Medication', '39', '5.4.1', 'Acceptable Concomitant Medications', '39', '5.4.2', 'Prohibited Concomitant Medications', '40', '5.5', 'Removal from Study Treatment and Withdrawal from Study', '40', '5.6', 'Study Discontinuation', '41', '6', 'TRIAL PROCEDURES AND ASSESSMENTS', '42', '6.1', 'Trial Procedures', '42', 'Confidential', 'Page 7 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '6.1.1', 'Administrative Procedures', '42', '6.1.2', 'Clinical Procedures/Assessments', '44', '6.1.3', 'Clinical Safety Laboratory Procedures/Assessments', '46', '6.1.4', 'Other Procedures', '47', '6.1.5', 'Visit Requirements', '48', '6.2', 'Assessment of Safety', '51', '6.2.1', 'Adverse Events and Laboratory Abnormalities Reporting', '51', '6.2.2 Handling and Reporting of Safety Parameters', '56', '7', 'ACCOMPANYING TRANSLATIONAL RESEARCH PROJECT', '58', '7.1', 'Sampling Time Points, Materials and Analyses', '58', '7.1.1 Processing and Storage of blood samples', '58', '7.1.2', 'Tissue Samples', '58', '7.1.3', 'Blood Samples', '59', '7.1.4', 'Analyses', '59', '8', 'STATISTICAL ANALYSIS', '60', '8.1', 'Justification of Sample Size', '60', '8.2', 'Analysis', '60', '8.2.1', 'Study Populations for Analysis', '61', '8.3', 'Further Analysis', '62', '9', 'STUDY MEDICATION', '63', '9.1', 'mFOLFOX-6', '63', '9.1.1 Oxaliplatin', '63', '9.1.2 Leucovorin', '64', '9.1.3 5-Fluorouracil', '64', '9.2', 'mFOLFOXIRI', '64', '9.2.1 Irinotecan', '64', '10 ADMINISTRATIVE AND REGULATORY DETAILS', '65', '10.1', 'Regulatory and Ethical Compliance', '65', '10.2', 'Registration and Request for Authorization of the Trial', '65', '10.3', 'Ethics Committee', '65', '10.4', 'Informed Consent', '66', '10.5', 'Insurance', '66', '10.6', 'Confidentiality', '66', '10.7', 'Confidentiality of Subject Records', '66', '10.8', 'Confidentiality of Investigator Information', '66', '10.9', 'Compliance with Financial Disclosure Requirements', '67', '10.10', 'Quality Management System', '67', '10.10.1 Quality Control and Quality Assurance', '67', '10.10.2Audits and Inspections', '67', '10.10.3Monitoring', '67', '10.11 Data Management', '68', '10.11.1 Plausibility Check, Data Cleaning and Coding', '68', '10.12 Publication and Registration of the Trial', '68', 'Confidential', 'Page 8 of 79']\n\n###\n\n", "completion": "END"}